The global burden of lung cancer: current status and future trends

被引:0
作者
Amanda Leiter
Rajwanth R. Veluswamy
Juan P. Wisnivesky
机构
[1] Icahn School of Medicine at Mount Sinai,Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine
[2] Icahn School of Medicine at Mount Sinai,Division of Hematology and Oncology, Department of Medicine
[3] Icahn School of Medicine at Mount Sinai,Division of General Internal Medicine, Department of Medicine
[4] Icahn School of Medicine at Mount Sinai,Tisch Cancer Institute
来源
Nature Reviews Clinical Oncology | 2023年 / 20卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer incidence and mortality rates differ substantially across the world, reflecting varying patterns of tobacco smoking, exposure to environmental risk factors and genetics. Tobacco smoking is the leading risk factor for lung cancer. Lung cancer incidence largely reflects trends in smoking patterns, which generally vary by sex and economic development. For this reason, tobacco control campaigns are a central part of global strategies designed to reduce lung cancer mortality. Environmental and occupational lung cancer risk factors, such as unprocessed biomass fuels, asbestos, arsenic and radon, can also contribute to lung cancer incidence in certain parts of the world. Over the past decade, large-cohort clinical studies have established that low-dose CT screening reduces lung cancer mortality, largely owing to increased diagnosis and treatment at earlier disease stages. These data have led to recommendations that individuals with a high risk of lung cancer undergo screening in several economically developed countries and increased implementation of screening worldwide. In this Review, we provide an overview of the global epidemiology of lung cancer. Lung cancer risk factors and global risk reduction efforts are also discussed. Finally, we summarize lung cancer screening policies and their implementation worldwide.
引用
收藏
页码:624 / 639
页数:15
相关论文
共 338 条
[121]  
Sindelar JL(2020)Association between diabetes mellitus and lung cancer: meta-analysis Eur. J. Clin. Invest. 110 1607-1842
[122]  
Campus B(2017)Obesity, metabolic factors and risk of different histological types of lung cancer: a Mendelian randomization study PLoS ONE 311 881-2899
[123]  
Fafard P(2008)The insulin-like growth factor pathway in lung cancer J. Thorac. Oncol. 7 825-975
[124]  
St Pierre J(2014)Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts Br. J. Cancer 374 1166-531
[125]  
Hoffman SJ(2014)Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA 7 296-68
[126]  
Bruce N(2016)The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis Oncotarget 18 1503-80
[127]  
Woolley KE(2016)Clinical implications of genomic discoveries in lung cancer N. Engl. J. Med. 63 503-1265
[128]  
Johnston FH(2017)AACR Project Genie: Powering precision medicine through an international consortium Cancer Discov. 93 395-1325
[129]  
Korsiak J(2012)Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers Clin. Cancer Res. 48 962-2406
[130]  
Rousseau M-C(2003)Risk for smoking-related cancer among relatives of lung cancer patients Cancer Res. 315 425-409